Montevideo, Uruguay August 31, 2018 – BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that Mr. Federico Wintour was appointed as the new Chief Executive Officer of Grupo Biotoscana. Mr. Mariano García-Valiño will continue supporting the Company as advisor to the Board of Directors. Change will be effective September 1st.
The Board of Director thanks Mr. García-Valiño for his important contributions to the Company over the past few years and welcome Mr. Wintour to the Company and his new attributions.
“I am very pleased to have Mr. Federico Wintour joining the company. His knowledge, experience and leadership will certainly help GBT move on to our next development phase, as we continue to strengthen our operations and focus on launching the robust pipeline of new products”, said Juan Pablo Zucchini, Chairman of the Board of Directors.
Mr. Federico Wintour has over thirty years of experience in the Latin America pharmaceutical market. Prior to joining GBT, Mr. Wintour worked at Vifor Pharma where he successfully managed the Latin America region, where he managed more than twenty countries and around fifty partners and distributors, for almost eight years. Previously, he worked during fourteen years at Merck (known as MSD outside US and Canada), where he served in multiple roles and various countries in Latin America, the latest one as Regional Managing Director for the Southern Cone Region.
“I am very excited with this new challenge and I am eager to lead the next chapter as CEO. GBT is a very interesting company with tremendous potential in Latin America. I am very impressed with the product portfolio and the pipeline. I look forward to working with GBT’s strong management team to continue to materialize GBT’s promising future “, said Federico Wintour.
Mr. Federico Wintour holds a degree in Economics from the Universidad de Buenos Aires and a master’s degree in Management and Strategic Marketing from the Universidad de Ciencias Empresariales y Sociales in Argentina. Federico will be based in the company’s headquarters in Montevideo, Uruguay.
About GBT Grupo Biotoscana
GBT Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM e Dosa. GBT’s strong portfolio combines world-class licenses and proprietary products.
To find out more about Grupo Biotoscana, please go to www.grupobiotoscana.com